# Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine

> **NCT04252742** · PHASE4 · COMPLETED · sponsor: **Amgen** · enrollment: 512 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Erenumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04252742
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-15
- **Primary completion:** 2023-10-26
- **Final completion:** 2023-10-26
- **Target enrollment:** 512 (ACTUAL)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04252742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04252742, "Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT04252742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*